HER2 Positive Breast Cancers Terminated Phase 2 / 3 Trials for Trastuzumab (DB00072)

Also known as: HER2 Positive Breast Cancer

IndicationStatusPhase
DBCOND0066412 (HER2 Positive Breast Cancers)Terminated2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02213744MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsTreatment